Jazz Pharmaceuticals plc (JAZZ) — Business segments and KPIs
Revenue by business segment and geography for Jazz Pharmaceuticals plc, with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Xywav | 1.66B | 39.6% |
| Epidiolex/Epidyolex | 1.06B | 25.3% |
| Rylaze/Enrylaze | 402.92M | 9.6% |
| Zepzelca | 307.31M | 7.3% |
| High Sodium AG Oxybate Product Royalty Revenue | 211.73M | 5.1% |
| Defitelio/Defibrotide | 199.39M | 4.8% |
| Vyxeos | 146.71M | 3.5% |
| Xyrem | 146.03M | 3.5% |
| Ziihera | 24.81M | 0.6% |
| Sativex | 16.28M | 0.4% |
| Other Products | 14.17M | 0.3% |
| Revenue by region | ||
| UNITED STATES | 3.83B | 89.8% |
| Europe | 341.12M | 8.0% |
| Other Countries | 94.87M | 2.2% |